Key result
Aromatase inhibitors improve breast cancer recurrence compared to tamoxifen, outweighing the potential risk of cardiovascular adverse events in most postmenopausal women.
Why the study?
Aromatase inhibitors are the preferred endocrine treatment in postmenopausal estrogen receptor-positive breast cancer, but concerns have been raised regarding their cardiotoxic potential.
Does treatment with aromatase inhibitors increase the risk of cardiotoxicity compared to tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer?
Does treatment with aromatase inhibitors increase the risk of cardiotoxicity compared to tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer?
While aromatase inhibitors may have cardiotoxic potential, their benefit in preventing breast cancer recurrence outweighs cardiovascular risks, highlighting the need for standard cardiovascular disease management in these patients.
May support aromatase inhibitor preference in most postmenopausal women; leaves open individualized CV risk assessment in prospective trials.
Summary With the success of modern cancer therapy, breast cancer survival has steadily improved over the last decades. Treatment with aromatase inhibitors has become the preferred endocrine treatment in postmenopausal women with estrogen receptor-positive breast cancer. However, concerns have been raised over a possible cardiotoxic potential. The aim of the current paper is to review the evidence regarding cardiotoxicity with aromatase inhibitors in breast cancer. Weighing benefits vs. risks, the improved effect of aromatase inhibitors vs. tamoxifen on breast cancer recurrence in most patients outweighs the potential risk of CV adverse events. At present it is advisable to ensure that standard measures of cardiovascular disease (CVD) management are applied to women with breast cancer, i.e., lifestyle intervention and if needed medical treatment of CVD and risk factors for CVD.
No takes yet. Share an insight, caveat, or question.
Lund et al. (2022) conducted a review in Estrogen receptor-positive breast cancer. Aromatase inhibitors vs. Tamoxifen was evaluated on Cardiovascular adverse events. Aromatase inhibitors improve breast cancer recurrence compared to tamoxifen, outweighing the potential risk of cardiovascular adverse events in most postmenopausal women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: